BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT

Multiple Myeloma Clinical Trial

Official title:

Safety and Efficiency of BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT: a Prospective, Single-arm, Single-center, Phase II Study.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05846737
• Other study ID #: CHAMPION-001
• Status: Recruiting
• Phase: Phase 2
• Start date: May 1, 2023
• Est. completion date: May 1, 2028

Study information

• Verified date: May 2023
• Source: Institute of Hematology & Blood Diseases Hospital
• Contact: Gang An, PhD&MD
• Phone: +86 022-23909171
• Email: angang[@]ihcams.ac.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a open-label, single-center Phase 2 study to evaluate the efficacy and safety of BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT. A total of 40 subjects will be enrolled into this study.

Description:

The study is a prospective, single-arm, single-centre, phase II study designed to evaluate the efficacy and safety of BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT. Patients with detectable MRD after undergoing ASCT MRD will be enrolled in this study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: May 1, 2028
• Est. primary completion date: May 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age = 18 years.

2. Participants with documented NDMM according to IMWG diagnostic criteria.

3. High-risk MM, as determined by R2-ISS(J Clin Oncol, 2022,40(29):3406-3418.), Stage III or Stage IV.

4. Has received 3 to 6 cycles of induction therapy, followed by conditioning regimen and ASCT.

5. Screening must be completed within 100 days of ASCT.

6. For subjects receiving consolidation therapy after ASCT, screening must be completed within 60 days after consolidation therapy, and within 6 months after ASCT.

7. Detectable MRD using EuroFlow or NGS, at 100 days after ASCT (minimum sensitivity of 10-5).

8. All screening blood biochemistry: tests should be performed according to the protocol and within 14 days before enrollment. Screening laboratory values must meet the following criteria: a.TBIL<1.5 x upper limit of normal (ULN) (<3 x ULN in patients with Gilbert's syndrome); b.AST and ALT <3 x ULN.; c. Creatinine clearance > 60mL/min (calculated using the Cockroft-Gault formula).

9. Routine blood tests (performed within 7 days, no RBC transfusion, no G-CSF/GM-CSF/platelet agonists, no drug correction within 14 days before screening, no PLT transfusion within 7 days) : WBC = 1.5 x 109/L, ANC = 1.0 x 109/L, Hb = 85 g/L PLT = 75 x 109/L (if BMPC < 50%) or PLT = 50 x 109/L (if BMPC = 50%).

10. Patients must be able to take prophylactic anticoagulant therapy as recommended by the study.

11. The woman is not breastfeeding, is not pregnant and agrees not to be pregnant during the study period and for the following 12 months. Male patients agreed that their spouse would not become pregnant during the study period and for 12 months thereafter.

Exclusion Criteria:

1. Primary plasma cell leukemia.

2. Documented active amyloidosis.

3. Multiple myeloma with central nervous system (CNS) invasion.

4. Has received maintenance therapy.

5. Prior exposure to any BCMA-targeted therapy or CAR-T therapy.

6. Patients with peripheral neuropathy greater than grade 2 or peripheral neuropathy greater than grade 2 with pain at baseline, regardless of whether they were currently receiving medical therapy.

7. Known intolerance, hypersensitivity, or contraindication to BCMA-CART cellular products.

8. Seropositive for human immunodeficiency virus (HIV).

9. Hepatitis B infection.

10. Hepatitis C infection.

11. Life expectancy of <3 months.

12. Women who are pregnant or breastfeeding.

13. Subjects had major surgery within 2 weeks before randomization (for example, general anesthesia), or is not fully recovered from the surgery, or surgery is arranged during study period.

14. Received live attenuated vaccine within 4 weeks prior to study treatment.

15. According to the researcher's judgment, any condition including but not limited to serious mental illness, medical illness, or other symptoms/conditions that may affect study treatment, compliance, or the capability of providing informed consent.

16. Necessary medication or supportive therapy is contraindicated with study treatment.

17. Any diseases or complications that may interfere with the study.

18. Patients are not willing to or cannot comply with study scheme.

Related Conditions & MeSH terms

• Multiple Myeloma

Intervention

Biological:
• anti-BCMA CAR-T
Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2-4 x 10^6 anti-BCMA CAR+T cells/kg.

Locations

Country	Name	City	State
China	Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences	Tianjin	Tianjin

Sponsors (1)

Lead Sponsor	Collaborator
Institute of Hematology & Blood Diseases Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	The CART cell duration in vivo	The copies of BCMA-CART DNA in peripheral blood with qPCR method	Up to 1 year
Primary	Safety and Tolerability	The incidence of treatment-emergent adverse events (TEAEs)	Up to 2 year
Primary	MRD-negativity rate	Achieving undetectable MRD, as determined by NGF/NGS 3 months after CAR-T cell infusion	3 months after CAR-T cell infusion
Secondary	Complete response rate (CRR)	CR or better is defined as percentage of participants who achieve a CR response or Stringent Complete Response (sCR) response accoording to the IMWG criteria	1 month after the CAR-T cell transfusion, after consolidation therapy
Secondary	Progression free survival (PFS)	Progression free survival is defined as the time from the date of diagnosis to the date of first documented PD, as defined in the IMWG criteria, or death due to any cause, whichever occurs first	Up to 2 year
Secondary	Overall Survival (OS)	Overall survival is measured from the date of diagnosis to the date of the participant's death.	Up to 5 year